PURPOSE: Bronchiectasis is a common disease in the Asia-Pacific and affected patients suffer from chronic sputum production and recurrent exacerbation. There are a variety of different pathogenesis involved in bronchiectasis . Immunomodulatory agent such as low-dose macrolides have also been shown to have some efficacy. Bronchiecatsis is associated with mild to moderate airflow obstruction that tends to worsen over time. The purpose of this study was to define the clinical and spirometric characteristics of Non-CF bronchectasis.
METHODS: A retrospective study of all patients who were diagnosed with bronchiectasis (2005-2009) was conducted at the Busan Paik Hospital, Inje University, in Busan. Data regarding age, sex, sputum and bronchial washing Gram stain and culture, spirometry, chest CT, medications,exacerbation history was obtained.
RESULTS: 138 (55 men and 83 women) bronchiectasis patients (mean age 58.4+/- 4.5 years) were studied. The most common symptoms were chronic sputum 38%, dyspnea 30%, hemoptysis 18%, cough 12%. Spirometry showed FEV1/FVC of 65.2% +/m 13.27 (range 30.32-91.38), FEV1% pred 67.4 +/- 11.47 (range 30.34-119.25). Airflow obstruction was detected in 80/138 (58%). The most frequent potential pathogenic microorganisms were P. aeruginosa 31%. 34/80 (42%) of patients with airflow obstruction were never smoker. 97 (25 men and 72 women) were followed up for more than 1 year. Mean length of low dose erythromycin theatment 6 months and 40 patients had low dose erythromycin treatment. There was a decrease in the exacerbation frequency from 0.75/month pre-erythromycin to 0.34/month (P<0.001) post-erythromycin.
CONCLUSIONS: Bronchiectasis should be considered in patients, females with chronic respiratory symptoms. Airflow obstruction is common in bronchiectasis and low dose erythromycin reduced the exacerbation frequency in bronchiectasis.
CLINICAL IMPLICATIONS: Low-dose erythromycin may be a beneficial effect upon exacerbation frequency in non-CF bronchiectasis.
DISCLOSURE: The following authors have nothing to disclose: Young Min Lee
No Product/Research Disclosure Information